Webpackaging logo

Schreiner MediPharm introduces label concept combining First-Opening Indication and Blinding for clinical trials

  • Schreiner MediPharm
Europe, Eating, Drinking, Health, Primary Packaging, Secondary Packaging, Active, Smart Packaging, Plastic, Glass

New Flexi-Cap for clinical trial supplies combines anti-counterfeit protection with reliable binding for transparent containers; Integrated Booklet-Label offers ample space for product info in different languages.

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for over 65 years, has a new addition to its Flexi-Cap product family: Flexi-Cap for Clinical Trial Supplies (CTS).
Schreiner MediPharm’s Flexi-Cap solutions irreversibly indicate first opening of primary containers, thus preventing illegal filling and reuse of empty containers with counterfeit substances. The new Flexi-Cap for clinical trials adds reliable blinding of transparent containers to this first-opening protection, accomplished through the use of opaque-printed film caps that prevent investigational products from being distinguished from one another.
The new Flexi-Cap for Clinical Trial Supplies consists of a label and two opaque-printed film caps that completely wrap around the container. While one cap encloses a container’s lid and upper portion, the second cap protects its bottom and lower sections. In this way, the solution ensures reliable blinding of transparent containers, combined with irreversible first-opening protection due to a tear strip integrated into the upper cap.
The need for this combination label concept arose from the requirement that product candidates in clinical trials be reliably blinded in order to achieve optimum test results. Since any visual differences between the active drug and the placebo – including variations in color – must not be discernible to trial subjects, labels need to meet special requirements when transparent containers are used. The new Flexi-Cap version also protects clinical trial supplies against tampering, and provides space for extensive product descriptions in diverse languages – a prerequisite for clinical trials to be efficiently and flexibly conducted in an international context.
Applied without heat, the solution is suitable for temperature-sensitive medicines. Flexi-Cap for Clinical Trial Supplies can be adapted to glass containers of various types, shapes and sizes and also protects against glass breakage. Various colors with high opacity may be used for the caps, and the lid of the film cap offers additional space that can be imprinted with codes or used for integration of NFC chips for interactive applications.
“Schreiner MediPharm is proud of the newest member of our Flexi-Cap family, which combines first-opening protection with reliable blinding in a unique fashion,” said Gene Dul, President of Schreiner MediPharm U.S. “This innovation speaks directly to the critical need for investigational products used in clinical trials to be both truly secure and indistinguishable from each other in order to assure successful research studies.”

See also

Schreiner MediPharm and Applied DNA Sciences offer forensic counterfeit-proof feature for pharma labels

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions, now offers a new forensic authentication feature for pharmaceutical labels in cooperation with Applied DNA Sciences. SigNature DNA is a high-security feature based on DNA markers with which pharmaceutical manufacturers can protect products against counterfeiting, and patients against potential health risks.

Schreiner MediPharm develops smart blister pack for clinical trial

Schreiner MediPharm has developed a smart blister pack for digital patient compliance monitoring to enhance medication adherence by clinical trial participants. Schreiner MediPharm implemented the smart packaging solution together with the Dutch technology company ECCT (Experts in Communications and Connectivity Technology). Employment of this electronic tool to manage and track processes during clinical trials marks a milestone for the pharmaceutical manufacturer.

Schreiner MediPharm supports Biotest AG with “Late Stage Customization” service for supply chain agility

Flexible production of functional labels successfully addresses market segmentation. Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions for over 65 years, recently implemented a special Late Stage Customization service in partnership with its customer, Biotest AG. The new process allows for faster production of functional labels on short demand. As a result, Biotest benefits from greater flexibility and is able to respond to market requirements with requisite agility, while Schreiner MediPharm assists its customer in meeting the demands of current segmentation trends in the pharmaceutical industry.

  • Company News
  • English
  • Modified 08 Jun 2017
  • Hits 618